Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)

BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular risk. The comparative effects among parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahaffey, Kenneth W., Neal, Bruce, Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Fabbrini, Elisa, Sun, Tao, Li, Qiang, Desai, Mehul, Matthews, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777572/
https://www.ncbi.nlm.nih.gov/pubmed/29133604
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777572/
https://www.ncbi.nlm.nih.gov/pubmed/29133604
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038

Ejemplares similares